The latest news, announcements and press releases from VIR Biotechnology.
Vir Biotechnology will receive $335M in upfront and near-term milestone payments, will split U.S. profit/loss equally with Astellas (50/50), and is eligible to receive up to an additional $1.37B in development, regulatory and sales milestones, along with tiered, double-digit royalties on ex-U.S. net sales -
This is the News section of the company profile page for VIR Biotechnology on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.